TY - JOUR
T1 - Porous Silicon Nanocarriers with Stimulus-Cleavable Linkers for Effective Cancer Therapy
AU - Xue, Yufei
AU - Bai, Hua
AU - Peng, Bo
AU - Tieu, Terence
AU - Jiang, Jiamin
AU - Hao, Shiping
AU - Li, Panpan
AU - Richardson, Mark
AU - Baell, Jonathan
AU - Thissen, Helmut
AU - Cifuentes, Anna
AU - Li, Lin
AU - Voelcker, Nicolas H.
N1 - Publisher Copyright:
© 2022 The Authors. Advanced Healthcare Materials published by Wiley-VCH GmbH.
PY - 2022/6
Y1 - 2022/6
N2 - Porous silicon nanoparticles (pSiNPs) are widely utilized as drug carriers due to their excellent biocompatibility, large surface area, and versatile surface chemistry. However, the dispersion in pore size and biodegradability of pSiNPs arguably have hindered the application of pSiNPs for controlled drug release. Here, a step-changing solution to this problem is described involving the design, synthesis, and application of three different linker-drug conjugates comprising anticancer drug doxorubicin (DOX) and different stimulus-cleavable linkers (SCLs) including the photocleavable linker (ortho-nitrobenzyl), pH-cleavable linker (hydrazone), and enzyme-cleavable linker (β-glucuronide). These SCL-DOX conjugates are covalently attached to the surface of pSiNP via copper (I)-catalyzed alkyne-azide cycloaddition (CuAAC, i.e., click reaction) to afford pSiNP-SCL-DOXs. The mass loading of the covalent conjugation approach for pSiNP-SCL-DOX reaches over 250 µg of DOX per mg of pSiNPs, which is notably twice the mass loading achieved by noncovalent loading. Moreover, the covalent conjugation between SCL-DOX and pSiNPs endows the pSiNPs with excellent stability and highly controlled release behavior. When tested in both in vitro and in vivo tumor models, the pSiNP-SCL-DOXs induces excellent tumor growth inhibition.
AB - Porous silicon nanoparticles (pSiNPs) are widely utilized as drug carriers due to their excellent biocompatibility, large surface area, and versatile surface chemistry. However, the dispersion in pore size and biodegradability of pSiNPs arguably have hindered the application of pSiNPs for controlled drug release. Here, a step-changing solution to this problem is described involving the design, synthesis, and application of three different linker-drug conjugates comprising anticancer drug doxorubicin (DOX) and different stimulus-cleavable linkers (SCLs) including the photocleavable linker (ortho-nitrobenzyl), pH-cleavable linker (hydrazone), and enzyme-cleavable linker (β-glucuronide). These SCL-DOX conjugates are covalently attached to the surface of pSiNP via copper (I)-catalyzed alkyne-azide cycloaddition (CuAAC, i.e., click reaction) to afford pSiNP-SCL-DOXs. The mass loading of the covalent conjugation approach for pSiNP-SCL-DOX reaches over 250 µg of DOX per mg of pSiNPs, which is notably twice the mass loading achieved by noncovalent loading. Moreover, the covalent conjugation between SCL-DOX and pSiNPs endows the pSiNPs with excellent stability and highly controlled release behavior. When tested in both in vitro and in vivo tumor models, the pSiNP-SCL-DOXs induces excellent tumor growth inhibition.
KW - anticancer
KW - controlled drug release
KW - porous silicon nanoparticles (pSiNPs)
KW - stimulus-cleavable linker
KW - surface chemistry
UR - http://www.scopus.com/inward/record.url?scp=85127372745&partnerID=8YFLogxK
U2 - 10.1002/adhm.202200076
DO - 10.1002/adhm.202200076
M3 - 文章
C2 - 35306736
AN - SCOPUS:85127372745
SN - 2192-2640
VL - 11
JO - Advanced Healthcare Materials
JF - Advanced Healthcare Materials
IS - 12
M1 - 2200076
ER -